Search results
Results from the WOW.Com Content Network
Estradiol valerate 10 mg + hydroxyprogesterone caproate 500 mg in an oil solution [15] Estradiol cypionate 2.5 to 10 mg + medroxyprogesterone acetate 12.5 to 50 mg in a microcrystalline aqueous suspension [15] [16] Estradiol enantate 5 to 50 mg + algestone acetophenide 75 to 200 mg in an oil solution [61] [15]
200 mg twice daily Finasteride: Propecia: 5αR inhibitor: Oral: 1–5 mg/day Dutasteride: Avodart: 5αR inhibitor: Oral: 0.25–0.5 mg/day Progesterone: Prometrium [c] Progestogen: Oral: 100–400 mg/day Medroxyprogesterone acetate: Provera: Progestogen: Oral: 2.5–40 mg/day Depo-Provera: Progestogen: IM: 150 mg every 3 mos: Depo-SubQ Provera ...
Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. [10] [4] It is used as a method of birth control and as a part of menopausal hormone therapy.
Medroxyprogesterone, also known as 6α-methyl-17α-hydroxyprogesterone or as 6α-methyl-17α-hydroxypregn-4-en-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone. [ 2 ] [ 3 ] It is specifically a derivative of 17α-hydroxyprogesterone with a methyl group at the C6α position.
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. [2] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. [2] It is recommended for short-term use and is given once a month by injection into ...
Medroxyprogesterone acetate (Amen, Curretab, Cycrin, Provera) – 2.5 mg, 5 mg, 10 mg Megestrol acetate (Megace) – 20 mg, 40 mg – approved specifically for the treatment of breast and endometrial cancer [ 46 ] and for the treatment of anorexia , cachexia , and weight loss in patients with AIDS Tooltip acquired immunodeficiency syndrome [ 47 ]
Since then, research has found that taking estrogen with a particular form of progesterone (medroxyprogesterone acetate) may increase the risk of breast cancer, but there was no effect when women ...
Progestogens that have been studied for potential use as POICs but were never marketed as such include the progesterone derivatives algestone acetophenide (dihydroxyprogesterone acetophenide) (100 mg/month), chlormadinone acetate (250 mg/3 months), hydroxyprogesterone caproate (250–500 mg/month), gestonorone caproate (2.5–200 mg/1–2 ...